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Abstract.  The membrane-anchored heparin-binding 
EGF-like growth factor precursor (proHB-EGF)/diph- 
theria toxin receptor (DTR) belongs to a class of 
transmembrane growth factors and physically associ- 
ates with CD9/DRAP27 which is also a transmem- 
brane protein. To evaluate the biological activities of 
proHB-EGF/DTR as a juxtacrine growth factor and 
the biological significance of its association with 
CD9/DRAP27,  the mitogenic activity of proHB-EGF/ 
DTR was analyzed using stable transfectants of mouse 
L cells expressing both human proHB-EGF/DTR and 
monkey CD9/DRAP27,  or either one alone. Juxtacrine 
activity was assayed by measuring the ability of cells 
in co-culture to stimulate DNA synthesis in an EGF 
receptor ligand dependent cell line, EP170.7. LH-2 
cells expressing human proHB-EGF/DTR stimulated 
EP170.7  cell growth moderately. However, LCH-1 
cells, a stable co-transfectant expressing both human 
proHB-EGF/DTR and monkey CDg/DRAP27 cDNAs, 
dramatically unregulated the juxtacrine growth factor 
activity of proHB-EGF/DTR approximately 25 times 
over that of LH-2 cells even though both cell types ex- 
pressed similar levels of proHB-EGF/DTR on the cell 
surface. Anti-CD9/DRAP27 antibodies which were 
not able to neutralize the mitogenic activity of soluble 
HB-EGF suppressed LCH-1  cell juxtacrine growth ac- 
tivity to the same extent as did anti-HB-EGF neu- 
tralizing antibodies and CRM  197, specific inhibitors 
of human HG-EGF. These findings suggest that op- 
timal expression of the juxtacrine growth activity of 
proHB-EGF/DTR requires co-expression of CD9/ 
DRAP27. These studies also indicate that growth fac- 
tor potentiation effects which have been observed pre- 
viously for soluble growth factors also occurs at the 
level of cell surface associated growth factors. 
H 
EPARIN-binding EGF-like growth factor (HB-EGF) t 
was first identified as a 20-22-kD glycoprotein by 
macrophages and macrophage-like cells (3, 18). It is 
structurally a  member of the EGF family which encom- 
passes  a number of structurally homologous  mitogens in- 
eluding EGF, transforming  growth factor-o~ ('l'GF-cx), vac- 
cinia virus growth  factor (VGF) (9),  amphiregulin  (AR) 
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1. Abbreviations  used in this paper:  AR, amphiregulin;  BASMC, bovine 
aortic smooth muscle cells; CSF-1, colony-stimulating factor-I; DT, diph- 
theria toxin; DTR, 171"  receptor;  EGFR, EGF receptor;  HB-EGF, heparin- 
binding-EGF;  hHB-EGF,  human  HB-EGF; HSPG,  heparan  sulfate pro- 
teoglycans; KL-1-2, e-kit ligand-l,2; TNF-ct, tumor necrosis faetor-ct; VGF, 
vaceinia virus growth factor. 
(43), and/5-cellulin (42). Like EGF, TGF-ct, and AR, HB- 
EGF binds to and stimulates phosphorylation of the EGF 
receptor. Secreted mature HB-EGF is a potent mitogen for 
NIH3T3 cells, bovine aortic smooth muscle cells (BASMC) 
(18, 20),  rat hepatocytes  (23),  and  human keratinocytes 
(16, 30). 
Analysis of the nucleotide sequence of human HB-EGF 
eDNA predicts a precursor protein of 208 amino acids com- 
posed of putative signal peptide, heparin-binding, EGF-like, 
transmembrane and cytoplasmic domains (18, 19, 47). The 
HB-EGF precursor can be cleaved to yield a mature biologi- 
cally  active  protein containing  75-86  amino acids  (19). 
While mature HB-EGF is a potent mitogen, there is also the 
possibility  that proHB-EGF  is biologically  active as well. 
For example, it has been shown that several growth factors 
and lymphokines  are synthesized  as membrane-anchored 
proteins,  including the EGF family of growth factors,  tu- 
mor necrosis factor-or (TNF-a), colony-stimulating factor-1 
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31). These transmembrane forms are biologically active. For 
example, the TGF-ot precursor in co-culture stimulate EGF 
receptor (EGFR) phosphorylation,  mitogenesis,  and  Ca  2+ 
uptake in which has been termed "Juxtacrine stimulation" (1, 
4,  6, 51).  Transmembrane  KL is required for the develop- 
ment of melanocytes,  germ cells, and hematopoietic  stem 
ceils. Soluble KL can not substitute for the transmembrane 
form in vivo (7,  14, 21). 
An important feature of proHB-EGF is that it is not only 
a growth factor precursor but that it acts as the specific recep- 
tor for diphtheria toxin (DT) and mediates endocytosis of the 
receptor-bound toxin resulting in its entry into the cytoplasm 
(25,  35).  Interestingly,  proHB-EGF/DT  receptor  (DTR) 
forms a complex with another membrane protein known as 
CD9 (25, 32). CD9 was first identified as a cell surface anti- 
gen on lymphohemopoietic cells (26, 27). It is identical to 
the  27-kD  diphtheria  toxin  receptor  associated  protein 
(DRAP27) (24). Anti-DRAP27 antibodies inhibit the bind- 
ing of DT to proHB- EGF/DTR and co-precipitate proHB- 
EGF/DTR and CD9/DRAP27 suggesting that these two pro- 
teins are closely associated in the cell membrane (24, 25). 
Furthermore,  co-expression of CD9/DRAP27 with proHB- 
EGF/DTR markedly enhances DT binding and DT sensitiv- 
ity of cells (8, 25, 32). The ability of CD9/DRAP27 to upreg- 
ulate DT sensitivity prompted us to investigate the role of 
CD9/DRAP27 in regulating I-IB-EGF growth factor activity, 
especially as a co-factor in juxtacrine  stimulation. 
Using  a  co-culture  system  of  donor  cells  expressing 
proHB-EGF/DTR in contact with acceptor cells expressing 
EGF receptor,  we demonstrate:  (a) that proHB-EGF/DTR 
stimulates cell growth in a juxtacrine manner;  and (b) that 
co-expression  of CD9/DRAP27  upregulates  proHB-EGF/ 
DTR juxtacrine growth factor activity to a great extent. 
Materials and Methods 
Materials 
Sulfo-NHS-Biotin and immobilized protein A were purchased from Pierce 
Chemical Co. (Rockford, IL). ECL-Western blotting kits were purchased 
from Amersham (Buckinghamshire, England). CRM197 was prepared as 
described previously (49). Anti-human HB-EGF antibodies, H6 (25), and 
M6  were  produced  by  immunizing  rabbits  with  synthetic  peptides 
GCK3RDRKVRDLQEADLDLLR  and  ENEEKVKLGMTNSH,  corre- 
sponding to amino acids 54-73 (extracellular domain) and 195-208  (cyto- 
plasmic  domain)  of the  human  HB-EGF  precursor,  respectively (18). 
Anti-human  HB-EGF  neutralizing  antibodies  were  directed  against  a 
75-amino acid form of recombinant human HB-EGF and prepared in goats 
by Deborah Datum (Scios Nova Inc., Mountain View, CA) (16). Anti-CD9 
monoclonal antibody, ALB-6, was purchased from MBL (Nagoya, Japan). 
Transfections 
Both transient and stable transfections were carried out using human I-IB- 
EGF  eDNA (19)  for the expression of proHB-EGF/DTR,  and monkey 
DRAP27  eDNA (32)  for the expression of CD9/DRAP27  as described 
previously (25).  Stable transfectants expressing proHB-EGF/DTR alone 
(LH-I, 2, 3, and 4) were derived from parental L cells and transfectants ex- 
pressing both proHB-EGF/DTR and CDg/DRAP27 (LCH-1) were derived 
from LCI4 cells, a CDg/DRAP27 transfccted cell line previously described 
(32). L cells and LCI4 cells (5  ×  105 cells) were transfocted with 20 #g 
of pRcI-IB-EGF  by the caicium-phospbate method (10),  cultured for 48 h 
and further cultured for 7 d in selection medium DME containing 10% FCS 
and 1 mg/mi G418.  Colonies growing in the selection medium were iso- 
lated and analyzed for 125I-DT binding as described previously (25). LH-I, 
LH-2, LH-3, and LH-d cells which express proHB-EGF/DTR at different 
levels, and LCH-I cells which express both proHB-EGF/DTR and CD9/ 
DRAP27 were passaged in culture and used for further ¢~tperiments. 
Human TOF-a cDNA was a kind gift from Dr. Rik Derynck (University 
of California, San Francisco, CA). A 720-bp HindIH-EcoRI fragment of 
TGF-a subcloned into pRK7a (ll) was inserted into a HindlH-EcoRI site 
of pBluescript II SK(-). The resulting plasmid containing TGF-a eDNA 
was digested at ApaI-XbaI sites. An ApaI-XbaI fragment was inserted into 
the  corresponding  restriction  enzyme  sites  in  the  expression  vector, 
pRc/CMV (Invitrogen Corp., San Deigo, CA). The resulting plasmid was 
transfected transiently as described previously (25)  by the calcium phos- 
phate method (10). 
Cell Culture and Growth Factor 
Activity Measurements 
L, LC, 3279-10,  and F-10 melanoma cell lines were grown in DME sup- 
plemented with 10% FCS, penicillin (100 U/mi) streptomycin (100 #g/ml). 
HB-EGF-transfected cell lines were cultured in the same media with the 
addition of G418  (0.5  mg/mi). EPI70.7 cells, obtained from Dr.  Jackie 
Pierce (NIH, Bethesda, MD) (37), were grown in RPMI 1640 medium sup- 
plemented with 10 % FCS, 5 % WEHI-3 cell conditioned medium, penicillin 
(100 U/ml), and streptomycin (100 #g/nil) (5). Human-mouse hybrid 3279- 
10 cells and its transfectants expressing CD9/DRAP27 were grown in DME 
supplemented with  10%  FCS, penicillin (100  U/re_l), streptomycin (100 
#g/mi), and 0.3  mg/mi G418 (32). 
Growth factor activity was monitored by measuring the incorporation of 
[3H]thymidine  into  the  DNA  of exponentially  growing  EPI70.7  cells. 
EP170.7 cells were washed twice with RPMI 1640 lacking WEHI-3 condi- 
tioned medium, and then plated at 2  ×  104 cells/well in a volume of 200 
#1 in 96-well plates. Samples of recombinant HB-EGF with and without 
blocking reagents were added and 36 h later, [3H]thymidine  (1 #Ci/weli; 
I mCi =  37MBq) was added to a well. After a 4-h incubation, the EPI70.7 
cells were harvested and [3H]thymidine  incorporated into DNA was mea- 
sured with the Betapfate system (Pharmncia LKB, Uppsaia, Sweden). 
The juxtacrine growth factor assays were carried out in several ways as 
follows: (a) Co-culture of formalin fixed transfectants  and EP170.7 cells: Pa- 
rental cells and transfectants of L cells, and human-mouse hybrid cells were 
plated in DME/10% FCS (500 #l/well) in 24-well plates and incubated for 
12  h  prior to washing and fixation.  The  cells were washed twice with 
DME/10% FCS/2 M NaCI to remove soluble HB-EGF trapped by cell sur- 
face heparan sulfate proteoglycans (34), and fixed with 5% buffered forma- 
lin for 5  rain.  The formalin fixed cells were washed twice with RPMI 
1640/10%  FCS and EP170.7 cells (1  ×  10  ~ cells/500 #l/well) were added 
in co-culture. After 48 h, [3Hlthymidine (1 #Ci/well;  1 mCi  ffi 37MBq) 
was added to the wells and the co-cultured cells were incubated for 4 h. The 
EPI70.7 ceils were harvested and analyzed for incorporation of 13H]thymi  - 
dine into DNA. (b) Co-culture of live transfected cells and EPI70.7 cells: 
transiently transfected L ceils were plated in DME/10% FCS (500 #l/well) 
in  24-well  plates,  incubated  for  12  h  and  washed  twice  with  RPMI 
1640110% FCS. Incubation with EPI70.7 cells and [3H]thymidine labeling 
EP170.7 cells was carried out as described in a. (c) Transwell plates: tran- 
sient transfectants of L cells were plated in DMEtI0% FCS (500 #l/well) 
in 24-well plates. After washing the cells either with or without fixation as 
described above,  the cells were covered with 250 #1 of RPMI 1640110% 
FCS. Transwells (12-ram diam, (14-#m pore size; Costar, Cambridge, MA) 
were introduced into the wells of the 24-well plate containing L cell trans- 
fectants and EPI70.7 cells (1  ×  105 cells/250 #l/well) were added to the 
Transwells. [3H]Thymidine labeling of EPI70.7 cells were carried out as 
described in a. 
Flow Cytometry 
Stably transfected cell lines were grown in 10 cm culture dishes at a density 
of 5  ×  105 cells/dish for 12 h.  To remove any soluble HB-EGF which 
might bind to heparan sulfate proteoglycans (HSPG) on the cell surface, 
ceils were washed twice with medium containing 2 M NaC1, and twice with 
PBS (34). The cells were detached from dishes with PBS containing 0.5 
mM EDTA, and centrifuged at 500 g  for 3 rain.  After washing the cell 
pellets twice with ice-cold PBS, the pellets were incubated with anti-HB- 
EGF antibody, H6, or anti-CD9 monoclonal antibody ALB-6 for 30 rain 
on ice. The cells were washed twice with ice-cold PBS and then incubated 
with  FITC-conjugated  goat  anti-rabbit  IgG  (Cappel,  Oregon Teknika, 
Durham, NC) or FITC-conjugated goat anti-mouse IgG (Bocton Dickin- 
son, San Jose, CA) on ice for 30 rain. The cells were washed twice with 
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window was set to eliminate dead cells and cell debris.  1 ×  104 cells were 
acquired by list mode, and measurements were performed on a single cell 
basis and displayed as frequency distribution histograms. 
Northern Blot Analysis 
Total RNA was isolated and analyzed by Northern blot from L and F-10 cells 
as described previously (12). Briefly an aliquot of total RNA (2.3 gg) was 
denatured  by formaldehyde, electrophoresed on a  1.2 % agarose gel, and 
transferred to a Hybond-N filter (Amersham Intl.,  Amersham,  UK). Hy- 
bridization  was  performed  with  single-stranded,  uniformly  32p-labeled 
eDNA probes corresponding to an EcoRI-XhoI fragment of  the mouse CD9 
gene. 
Cell Surface Biotinylation,  Immunoprecipitation, and 
Western Blotting 
LH and LCH cells (3  ×  106 cells) were grown overnight in 10 cm dishes. 
Cells were washed three times with ice-cold Hanks buffer, and biotinylated 
by 30-min incubation on ice with 0.1 mg/ml of sulfo-NHS-biotin (Pierce 
Chemical Co., Rockford, IL) in 100 mM Hepcs, pH 8.0, 0.15 M NaC1. Ex- 
cess reagent was quenched and removed by washing with DME/10% FCS. 
Cells were lysed with a lysis buffer (500 gl of 1% Triton X-100, 3 mM 
EDTA, 1 mM benzamidine,  1 mM p-amidino phenylmethylsulfonyl fluo- 
ride, 5 #M 3,4-dichloroisocoumarin, 10/zg/ml Aprotinin, and 0.4 M NaCI 
in 20 mM Hepes, pH 7.2). Supernatants of the cell lysates were incubated 
for 2 h at 4°C with 10/~g of H6 IgG followed by the incubation for 2 h at 
4°C with 10/zl of protein A trisacryl (50% suspension) (Pierce Chemical 
Co.). Sample,  s were dissolved in SDS-PAGE  sample buffer and fractionated 
by 15 % SDS-PAGE. Proteins in the gels were transferred to a nitrocellulose 
membrane (Schleicher & Sehuell, Dassel, Germany) in 150 mM 3-[cyelo- 
hexylamino]-l-propane-sulfonic acid (CAPS) buffer, pH 11, containing 20 % 
methanol at 180 mA for 3 h. The nitrocellulose membrane was blocked with 
5% skimmed milk in PBS and incubated for 30 rain at room temperature 
with avidin-HRP  (Vectastatin, Burlingarne, CA).  HRP  was detected  by 
ECL kit (Amersham) and autoradiography. Intensity of bands exposed to 
a X-OMAT film (Kodak, Rochester, NY) was measured with the Scanning 
Imager (Molecular Dinamics, Sunny Vale, CA). 
Results 
proHB-EGF/DTR Mediates Mitogenic Activity in a 
Juxtacrine Manner 
To test the potential juxtacrine activity of  proHB-EGF/DTR, 
we developed a co-culture system in which donor cells ex- 
pressing  proHB-EGF/DTR and  acceptor cells  expressing 
EGFR but not HB-EGF were incubated together. For the lat- 
ter, EP170.7 cells were chosen, since they are uniquely IL-3 
dependent but have been transfected with EGFR and respond 
only to EGFR ligands in the absence of IL-3. Mouse L cells 
transfected with human HB-EGF (hHB-EGF) eDNA were 
used as the source of membrane-anchored growth factor. 
Since previous studies showed that L cells transfected with 
hHB-EGF eDNA produce substantial proHB-EGF/DTR on 
the cell surface but also spontaneously release some soluble 
HB-EGF into the conditioned media (25), these cells were 
fixed with 5 % buffered formalin prior to co-culture to pre- 
vent processing, a method previously used to analyze cell as- 
sociated CSF-1  (46). The EP170.7 cells were overlaid on to 
a fixed monolayer of L cells and co-cultured for 48 h. The 
contact-dependent growth stimulation of EPI70.7 cells by 
L cells was then assayed by measuring the incorporation of 
[3H]thymidine into EP170.7  cell DNA.  Mock L cell trans- 
fectant did not stimulate EP170.7  cell growth under these 
conditions  (Fig.  1 A).  However, hI-IB-EGF-transfected L 
cells stimulated the growth of EP170.7  cells in proportion 
to the number of L cells plated.  At 20  x  10  ~ L cells,  a 
4,500-fold increase  in  EP170.7  DNA  synthesis  was  seen 
compared to control mock transfectants (465,000 cpm vs. 
103 cpm) (Fig. 1 A). As a control, the hHB-EGF-transfected 
L cells did not stimulate parental 32D cells lacking EGFR 
(data not shown). To determine whether a juxtacrine cell-to- 
cell contact mechanism was involved in stimulating EP170.7 
cell growth in the co-culture system, the two cell types were 
grown in Transwells so that EP170.7 cells and L cells were 
separated physically but diffusion of soluble HB-EGF could 
occur. As shown in Fig. 1 A, this procedure abrogated more 
than  90%  of EP170.7  cell growth  induced by hHB-EGF 
transfectants at 20  x  1@ cells/well. Moreover, conditioned 
media prepared from fixed hHB-EGF transfectants at 20  x 
104  cells/ml  co-cultured with  and  without  EP170.7  cells 
were tested for EP170.7 cell DNA synthesis in order to esti- 
mate the level of released HB-EGE Mitogenic activities in 
both the conditioned media were undetectable level. These 
results suggested that growth stimulation of EP170.7 cells by 
co-cultured hHB-EGF transfectants is mediated mainly by 
cell-to-cell  contact  via  proHB-EGF/DTR-EGFR  interac- 
tions in a juxtacrine manner. 
To ensure that no artifact of co-culture occured with fixed 
cells, the juxtacrine activity of proHB-EGF/DTR was also 
analyzed in a  co-culture of live non-fixed cells.  Live HB- 
EGF transfectants greatly enhanced EP170.7 cell prolifera- 
tion,  about  16-fold  over mock transfectants  at  5  x  104 
cells/well (Fig.  1 B). Physical blocking of cell-to-cell con- 
tact in Transwells abrogated EP170.7  cell growth by about 
40% (Fig. 1 B), suggesting that while live L cells stimulate 
EP170.7 cell proliferation in a juxtacrine manner, a substan- 
tial amount of paracrine activity mediated by a soluble HB- 
EGF occurred in the live cell co-culture as well. In fact both 
conditioned media prepared from hHB-EGF transfeetants at 
5  x  104 cells/ml with and without EP170.7  cells induced 
DNA synthesis of EP170.7  cells corresponding to 20-30% 
activity of the total activity shown in the co-culture at 5  x 
104 cells of hHB-EGF transfectants. Given the undetectable 
level of HB-EGF paracrine activity in the fixed L cell co- 
culture unlike that in live cells, this method was chosen as 
the best way to measure proI-IB-EGF/DTR juxtacrine ac- 
tivity. 
A series of four LH cell lines were cloned and analyzed 
quantitatively for both juxtacrine activity and for proHB- 
EGF/DTR protein levels by flow cytometry using an anti- 
body  (H6)  directed  against  the  extracellular  domain  of 
proHB-EGF/DTR.  These  cell  lines  were  named  LH-1, 
LH-2, LH-3, and LH-4 in order of increased cell surface 
proI-IB-EGF/DTR expression as measured by flow cytome- 
try (data not shown). In addition, the expression of cell sur- 
face  proHB-EGF/DTR  was  analyzed  quantitatively  by  a 
combination of  cell surface biotinylation and immunoprecip- 
itation using an antibody (M6) that recognizes the cytoplas- 
mic domain of proHB-EGF/DTR, and which as a  conse- 
quence immunoprecipitates proHB-EGF/DTR specifically, 
but can not precipitate any soluble forms of mature HB-EGF 
potentially trapped by cell surface HSPG. As shown in Fig. 
2  A,  proHB-EGF/DTR migrated  as  heterogeneous mole- 
cules with molecular masses of about 20, 24, and 27 kD on 
SDS-PAGE, consistent with our previous report (25). The 
expression level of  proHB-EGF/DTR in the four L cell trans- 
fectants was estimated by measuring the intensities of the 
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proI-IB-EGF/DTR.  Formalin fixed (A) or non- fixed (B) L  cells 
transiently  transfected  with I-IB-EGF eDNA and plated  at various 
number of cells/well  were co-cultured with 1 x  105 EP170.7 cells 
and after 48 h, the incorporation of [3H]thymidine  into EP170.7 
cell DNA was measured,  o,  Mock- transfected  L cells;  o, tran- 
siently transfected  L cells. (T-well)  Co-culture was also carried out 
in Transwells (T-well) using 20  x  104 fixed HB-EGF transfected 
L cells/well  (bar graph in A; m, mock; H, HB-EGF) or 5  x  104 
unfixed  I-IB-EGF-transfected  L  cells/well  (bar  graph  in  B;  m, 
mock; H, HB-EGF). (CM) EP170.7 cell DNA synthesis assay was 
carried out to estimate the mitogenic activities  in the media condi- 
tioned by 20  x  104 fixed HB-EGF-transfected L cells alone (bar 
graph in A; a), 20  x  104 fixed I-IB-EGF-transfected  L cells  with 
1 x  10s EP170.7 ceils  (bar graph in A; b), 5  ×  104 un-fixed HB- 
EGF-transfected L cells alone (bar graph in B; a) and 5 x  104 un- 
fixed HB-EGF-transfected L cells with EP170.7 cells (bar graph in 
B; b). 
bands using a  densitometer  (Fig.  2  B).  LH-2,  LH-3,  and 
LH-4 cells  expressed  2.8,  14,  and  73  times  more  immu- 
noprecipitable  proHB-EGF/DTR than  LH-1  ceils,  respec- 
tively. The L cells and the four stable transfectants were fixed 
and co-cultured with EP170.7 cells and their growth stimula- 
tory activities were measured (Fig. 2 C). Unlike L cells, four 
LH cell  transfectants  promoted  EP170.7  cell  growth.  The 
growth factor activities of LH-2, LH-3, and LH-4 cells were 
2.6,  13, and 61 times greater than that of LH-1 cells, respec- 
tively,  at  10  x  104 cells/well.  Thus the juxtacrine activity 
of the LH transfectants  correlated positively with proHB- 
EGF/DTR cell surface levels in a very quantitative manner. 
Coexpression of CDg/DRAP27 with 
proHB-EGF/DTR Greatly Enhances Juxtacrine 
Growth Stimulation Activity 
Previous studies on the diphtheria toxin receptor indicated 
that proHB-EGF/DTR forms a complex with CD9/DRAP27 
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Figure 2. proHB-EGF/DTR protein levels on the cell surface  and 
juxtacrine growth factor activities on HB-EGF-transfected L cells. 
(A) Immunoprecipitation of proHB-EGF/DTR. Cell  surface pro- 
teins were biotinylated  and the proHB-EGF/DTR was immunopre- 
cipitated with anti-HB-EGF antibodies  (M6) from L cells (lane 1 ) 
and  four HB-EGF-transfected cell  lines  (lane  2,  LH-1; lane  3, 
LH-2; lane 4, LH-3; lane 5, LH-4). The immunoprecipitaP-.d pro- 
tein was fraetionated  by SDS-PAGE and after transfer to a nitrocel- 
lulose  membrane,  the  biotinylated  proteins  were  probed  with 
avidin-HRP and detected by autoradiography.  Bands pointed out by 
an arrowhead  were  nonspecifically  detected.  (B)  Densitometric 
analysis of the immunoprecipitated  proHB-EGF/DTR shown in A. 
For each cell  type, the  intensities  of the  immunoreactive  bands 
ranging from 20-27 kD were measured together.  (C) Juxtacrine 
growth factor activities  of L  cells  and the  four stable  HB-EGF 
transfectants.  Cells were plated at  10  x  104 cells/well  and juxta- 
crine activity was measured as in Fig.  1 A. 
in the cell membrane and that CD9/DRAP27 enhances the 
number of functional diphtheria  toxin receptor without an 
increase  in  the  number  of cell  surface  proHB-EGF/DTR 
molecules  (25).  Accordingly, we  analyzed whether  CD9/ 
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DTR as well. Northern blot analysis showed that transcripts 
of the CD9 gene were undetectable in L  cells but that the 
probe could detect CD9 mRNA in a control melanoma F-10 
cell line (Fig. 3 A). Thus, monkey CD9/DRAP27 eDNA was 
co-transfected with HB-EGF eDNA into L cells, and a stable 
transfectant cell line (LCH-I) was cloned. A stable transfec- 
tant expressing CD9/DRAP27 alone (LC) was also cloned. 
CD9/DRAP27  protein expression in  both  LCH-1  and  LC 
cells was analyzed by flow cytometry and shown to be about 
equivalent  (Fig.  3  B).  Quantitative  immunoprecipitation 
demonstrated that LCH-1 cells (Fig. 4 A, lane 4) produced 
1.3  times more proHB-EGF/DTR than did the LH-2 cells 
(Fig. 4 A, lane 2), and about 20 times less than LH-4 cells 
(Fig. 4 A, lane 3). The juxtacrine growth factor activities of 
LH-2 and LCHq cells were compared (Fig. 4 B), and de- 
spite a comparable production of proHB-EGF/DTR, LCH-1 
cells displayed about 33 times more juxtacrine activity than 
did LH-2 cells at 5  x  I(P cells/well.  Actually the LCH-1 
cells displayed even more juxtacrine activity, 2.8-fold at 5  x 
104 cells/well, than did LH-4 cells, which are high expres- 
sors ofproHB-EGF/DTR (Fig. 4 A, lane 3). LC cells showed 
very little, if any, juxtacrine activity. These results suggested 
that CD9/DRAP27 upregulate proHB-EGF/DTR  juxtacrine 
activity to a large extent. 
Neutralization of  proHB-EGF/DTR Activity 
The anti-H-B-EGF neutralizing antibody which specifically 
neutralizes the mitogenic activity of human HB-EGF but not 
other EGF family members such as EGE TGF-ot, AR, and 
/3-cellulin (16), inhibited approximately 90 % of EP170.7 jux- 
B !1  L 
Fluorescence Intensity 
Figure 3.  Expression of CD9/DRAP27. (A) Expression of CD9 
mRNA in L cells. L cell and control mouse melanoma F-10 cell 
RNAs were subjected to Northern blotting using a mouse CD9 
cDNA probe. (B) CD9/DRAP27 protein expressed on L, LC, and 
LCH-1 cells. The cells  were incubated with anti-CD9 antibody 
ALB6, then with F1TC-conjugated  goat anti-mouse IgG, and fluo- 
rescence intensity was measured by flow cytometry. 
B 
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Figure 4. Upregulation of proHB-EGF/DTR juxtacrine growth fac- 
tor activity of CD9/DRAP27 co-expression. (A) Immunoprecipita- 
tion of pro-HB-EGF/DTR,  proHB-EGF/DTR produced  by  LC 
(lane 1) and L cell FIB-EGF transfectants, LH-2 (lane 2), LH-4 
(lane 3), and LCH-1 (lane 4) was biotinylated, immtmoprecipitated 
with anti-HB-EGF  antibody M6, and after SDS-PAGE analyzed 
with avidin-HRPO. (B) Juxtacrine growth factor activity. The four 
cell lines described in A were co-incubated with EPI70.7 cells and 
juxtacrine growth factor activity measured as in Fig. 1 A. LC (o), 
LH-2 (a,), LH-4 (A) LCH-I (e). 
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Figure  5.  Neutralization  of proHB-EGF/DTR juxtacrine  growth 
factor activity.  (A) Inhibition  of EP170.7 cell growth induced by 
proHB-EGF/DTR in a juxtacrine manner.  Anti-I-IB-EGF blocking 
antibodies,  CRM197, or anti-CD9 antibodies,  at the indicated con- 
eentrations,  were added to EP170.7 cells (2  x  104 cells/well)  be- 
ing  co-cultured  with  L  cell  I-IB-EGF  transfectants  (1  x  105 
cells/well).  LH-4 cells,  white  bars: LCH-1  cells,  gray bars.  (B) 
Effect  of anti-CD9  antibodies  on a  secreted  from of I-IB-EGE 
Anti-CD9 antibodies,  anti-HB-EGF blocking antibodies or CRM- 
197, at the indicated  concentrations,  were added to 2 rig/20 #l of 
75 amino acid recombinant mature human HB-EGF (46), the mix- 
tures were added to a 96-well plate of EP170.7 cells and the ability 
to stimulate  DNA synthesis  in EP170.7 cells  was measured. 
tacrine cell growth stimulated by LH-4 or LCH-1 cells (Fig. 
5 A). CRM  197,  a  non-toxic mutant of DT which binds to 
proHB-EGF/DTR and inhibits soluble HB-EGF specifically 
but not other EGF receptor ligands,  such as EGF,  TGF-tx, 
AR, and B-cellulin (33) also inhibited over 90% of the juxta- 
crine growth activities of these two cell lines.  These results 
confirmed that the growth stimulation  of EP170.7  cells  by 
L  cell transfectants was due to proHB-EGF/DTR and not to 
other EGFR ligands.  Since CDg/DRAP27 upregulated the 
juxtacrine growth activity of proHB-EGF markedly,  and a 
tight  physical  association  between  proHB-EGF  and  CD9/ 
A 
20  [  C15-2 
C7-1 
>¢  ?!7g-10 
0 
0 
B 
10 
106  107 
Expression  Level of CD9/DRAP27 
(molecules~cell) 
10  50  1  10  1 
I  It  It 
~=  =a  ~  "~. 
l o  (~  g/rnO 
I 
Figure 6.  Effect of CD9/DRAP27 co-expression  on the juxtacrine 
growth  factor  activity  of human-mouse  hybrid  cells.  (A)  Hu- 
man-mouse hybrid 3279-10 cells and three stable transfectants  ex- 
pressing  variable  amount of CD9/DRAP27 were plated  at 2  x 
105 cells/well  and juxtacrine  growth factor activity for EP170.7 
cells was measured as in Fig.  1 A. The numbers of CD9/DRAP27 
molecules  on the cell surface were determined by binding experi- 
ments with a saturating  amount (100 #g/ml) of 125I-labeled anti: 
DRAP27 ab (007) at 4°C for 6 h (32). (B) Neutralization  ofjuxta- 
trine activity. Anti-HB-EGF blocking antibodies,  anti-CD9 anti- 
bodies (ALB6), and CRM 197 were added to co-cultures of C15-2 
cells (the highest expressor of CD9/DRAP27) and EP170.7 cells at 
2  x  105 cells/well  and juxtacrine activity  measured as in A. 
DRAP27 on the cell membrane has been  shown (25),  the 
effect of  anti-CD9 antibodies on the juxtacrine growth factor 
activity  of cell  surface  proI-IB-EGF was  also  tested.  The 
anti-CD9 antibodies at  10 #g/ml suppressed the juxtacrine 
growth factor activity of LCH-1 cells by 75 %,  but had no 
effect on the juxtacrine growth factor activity of LH-4 ceils 
(Fig.  5 A). These results demonstrated that anti-CD9 anti- 
bodies  did  not directly inhibit  proHB-EGF juxtacrine  ac- 
tivity,  but  inhibited  indirectly  probably  due  to  the  steric 
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strated by showing that anti-CD9 antibodies did not inhibit 
the mitogenic activity of soluble mature HB-EGF whereas 
anti-HB-EGF  neutralizing  antibodies  and  CRM197  in- 
hibited this activity totally (Fig. 5 B). 
Dose-dependent Up-regulation of 
proHB-EGF/DTR Juxtacrine Activity by 
CDg/DRAP27 in Cells Expressing Endogenous 
Human proHB-EGF/DTR 
As  described  above,  L  cells  transfected  with  hHB-EGF 
showed significant growth stimulation of EP170.7 cells in a 
juxtacrine  manner  and  co-expression  of  CD9/DRAP27 
markedly enhanced its  activity.  However,  these  cells  are 
transfectants that over-express proHB-EGF/DTR and may 
not reflect a  situation in  which  proHB-EGF/DTR is  ex- 
pressed naturally. Therefore, the potentiating effect of CD9/ 
DRAP27 on the juxtacrine activity of proHB-EGF/DTR in 
3279-10  cells which express proHB-EGF/DTR was exam- 
ined naturally. The cell line 3279-10 is a hybrid cell line of 
human skin fibroblasts and mouse L  cells, which carried 
only two human chromosomes 5 and 22 (17). Human HB- 
EGF/DTR and CD9/DRAP27 are located in chromosome 5 
(13) and chromosome 12 (2), respectively. As expected the 
cell  line  expresses  human HB-EGF/DTR but not human 
CD9/DRAP27 (32).  CD9/DRAP27 cDNA was transfected 
into 3279-10 cells and three stable transfectants C7-1, C7-3, 
and C15-2 were isolated which expressed different levels of 
CD9/DRAP27 (32).  The juxtacrine activities of these cell 
lines were measured as a function of CD9/DRAP27 expres- 
sion (Fig. 6 A). The levels ofjuxtacrine growth factor activ- 
ity correlated positively with the level of  CD9/DRAP27 anti- 
gen on the cell surface (Fig. 6 A). In addition, the juxtacrine 
activity expressed by the highest CD9/DRAP27 expressor, 
C15-2,  was neutralized by anti-HB-EGF neutralizing anti- 
bodies, by CRM 197 and by anti-CD9 antibodies to about 
20% of control, which is equivalent to the juxtacrine growth 
Figure 7. Effect  of CD9 co-expression  on the juxtacrine growth fac- 
tor activity of proTGF-c~. Formalin fixed L cells transiently trans- 
fected  with HB-EGF cDNA or TGF-o~  cDNA, or cotransfected  with 
CD9/DRAP27 cDNA, and plated at 2 x  1@ cells/well in 24-well 
plates were co-cultured with 1 ×  l0  s EP170.7 cells. After a 48-h 
incubation, the incorporation of [3H]thymidine  into EP170.7 cell 
DNA was measured. 
factor activity of  327940 cells not expressing CD9/DRAP27 
(Fig. 6 B). Thus, the potentiating activity of CD9/DRAP27 
could be demonstrated for both transfected and endogenous 
proHB-EGF/DTR. 
Coexpression of  CD9/DRAP27 Does Not Upregulate 
proTG  F-a Activity 
To evaluate the specificity of CD9/DRAP27  on the juxta- 
crine  activity  of  proHB-EGF,  we  tested  the  effect  of 
CD9/DRAP27 on proTGF-o~  juxtacrine activity transiently 
expressed on L cells. Transient transfectants of  proTGF-(~ ex- 
pressed  significant juxtacrine  activity as  compared  with 
mock  transfectants as  well  as  did  proHB-EGF  transient 
transfectants  (Fig. 7). While cotransfection of CD9/DRAP27 
cDNA upregulated the juxtacrine growth factor activity of 
proHB-EGF for a great extent, it did not alter the juxtacrine 
activity of proTGF-o~ at all. These results suggest that CD9/ 
DRAP27 might be an unique upregulator for proHB-EGF, 
and that an NH2-terminal  extended sequence, heparin-bind- 
ing domain, existed in proHB-EGE  but not in proTGF-c~ 
might be required for the upregulation of its juxtacrine ac- 
tivity. 
Discussion 
We have demonstrated in these studies that: (a) HB-EGF ex- 
ists in a cell-associated form, proHB-EGF/DTR, which is a 
juxtacrine growth factor for cells expressing EGFR; and (b) 
proHB-EGF/DTR juxtacrine growth factor activity is up- 
regulated  markedly  by  another  transmembrane  protein 
known as CD9/DRAP27.  Previously, most studies on I-IB- 
EGF have involved the secreted form, a 20-22-kD protein 
mitogenic in a paracrine manner for cells such as fibroblasts, 
SMC and keratinocytes. However, the open reading frame of 
HB-EGF cDNA predicts an HB-EGF precursor form which 
could be processed to a mature secreted form. When mouse 
L cells are transfected with human HB-EGF cDNA encoding 
the  whole  precursor  molecule,  they express  cell  surface 
proHB-EGF/DTR that is found in 20-, 24-, and 27-kD forms 
as determined by flow cytometry and immunoprecipitation 
with highly specific anti-HB-EGF antibodies. These multi- 
ple forms might represent different glycosylation forms of 
HB-EGF which has been shown to be a glycoprotein or mul- 
tiple forms produced by processing as shown for mature HB- 
EGF (19). 
Juxtacrine activity can be demonstrated by the ability of 
L cells transfected with HB-EGF cDNA to stimulate in co- 
culture, DNA synthesis in EP170.7 cells, a myeloid ceU line 
engineered to express EGFR (37).  The parental cell line of 
EP170.7, 32D, is not stimulated by HB-EGF-transfected cells 
in a juxtacrine manner nor are parental L cells capable of 
stimulating  juxtacrine activity. The level ofjuxtacrine stimu- 
lation correlates positively with the number of transfected 
L cells used and the amount of proHB-EGF/DTR being pro- 
duced as monitored by flow cytometry and immunoprecipi- 
tation. To show that these proHB-EGF/DTR-EGFR juxta- 
crine interactions were mediated by cell-cell contact, cells 
were plated in a Transwell dish in which the proHB-EGF/ 
DTR-transfected L cells were physically separated from the 
EP170.7 cells.  Under these conditions, virtually no juxta- 
crine growth factor activity occurred. Further, neither of the 
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the  fixed cells  co-cultured with EP170.7 cells  stimulated 
EP170.7 cell DNA synthesis. In our experiments, juxtacrine 
activity was measured using formalin-fixed L cell I-IB-EGF 
transfectants so as to eliminate the possible processing of 
precursor to mature HB-EGF during the co-culture. Previ- 
ous studies have shown that proHB-EGF/DTR can be pro- 
cessed to mature HB-EGF, for example, by phorbol esters 
(38). When living, non-fixed, L cell transfectants rather than 
fixed one were used in Transwell experiments and the condi- 
tioned media from the non-fixed transfectants co-cultured 
with and without EP170.7 cells were examined, about 20- 
60 % of the total mitogenic activity persisted suggesting that 
in living cells, a degree of processing occurs giving rise to 
substantial paracrine activity. As a consequence, fixed cell 
co-cultures were used throughout the study in order to mea- 
sure strictly juxtacrine activity. In another study, it was found 
that proHB-EGF/DTR purified from baculovirus-infected 
insect cells was mitogenic consistent with the ability of this 
form of  HB-EGF to be mitogenlc in ajuxtacrine manner (36). 
Taken together, all of  the evidence demonstrates that proHB- 
EGF/DTR is a juxtacrine growth factor capable of stimulat- 
ing DNA synthesis in adjacent cells expressing the EGFR. 
Therefore, HB-EGF is  similar in this activity to TGF-c¢, 
TNF-~x, CSF-1, and the c-kit ligand, all of which are capable 
of juxtacrine activity (31). 
Recently, it was demonstrated that the receptor for diph- 
theria toxin is the same molecule as the HB-EGF precursor 
(25, 35). In the course of analyzing DT sensitivity of cells, 
it was found that a 27-kD transmembrane protein identical 
to the CD9 antigen increased cell sensitivity to DT toxicity 
(32).  This protein was found to associate physically with 
DTR and was named diphtheria toxin receptor associated 
protein 27,  or DRAP27  (32).  CD9/DRAP27  up-regulates 
DT sensitivity without altering the number of cell surface 
proHB-EGF/DTR molecules (25). Although the mechanism 
of CD9/DRAP27 action is unknown, a tight interaction of 
proHB-EGF/EII'R and CD9/DRAP27 is implied by the abil- 
ity of anti-CD9/DRAP27 antibodies to co-precipitate these 
two molecules. The tight association with CD9/DRAP27 
might somehow activate proHB-EGF/DTR and increase its 
functionality. 
We  have  found  that  CD9/DRAP27  also  up-regulates 
proHB-EGF/DTR juxtacrine activity quite markedly. When 
two transfected L cell lines express similar levels of cell sur- 
face proHB-EGF/DTR but one of them expresses, in addi- 
tion, CD9/DRAP27,  the juxtacrine activity of the proHB- 
EGF/DTR and CD9/DRAP27  co-expressants is increased 
about  25-fold  over  the  L  cells  expressing  proHB-EGF/ 
DTR  only.  CD9/DRAP27  expression  increases  proHB- 
EGF/DTR juxtacrine activity but does not increase proHB- 
EGF/DTR levels  suggesting a  potentiation activity rather 
than the induction of de novo proHB-EGF/DTR synthesis. 
The potentiating activity of CD9/DRAP27 for proHB-EGF/ 
DTR juxtacrine activity can also be demonstrated for cells 
producing endogenous proHB-EGF/DTR. The human-mouse 
hybrid cell line, 3279-10, has human chromosome 5, which 
is where the HB-EGF/DTR gene maps (13), but lacks chro- 
mosome 12, which is where CD9/DRAP27 maps (2). Typi- 
cally, 3279-10 cells show only a moderate amount of DT sen- 
sitivity (32)  and of proHB-EGF/DTR juxtacrine activity. 
However,  when these cell lines are transfected with CD9/ 
DRAP27, juxtacrine activity is increased in direct propor- 
tion to the amount of CD9/DRAP27 expressed. The role of 
CD9/DRAP27 in potentiating proHB-EGF/DTR juxtacrine 
growth factor activity is further demonstrated in that anti- 
CD9 antibodies, which do not inhibit HB-EGF mitogenic ac- 
tivity directly, will inhibit juxtacrine activity in cells co- 
expressing both transmembrane proteins to base-line levels 
found in the absence of CD9/DRAP27 expression. Taken to- 
gether,  it is quite evident that CD9/DRAP27  upregulates 
proHB-EGF/DTR juxtacrine growth factor activity dramati- 
cally. The mechanism for the CD9/DRAP27 effect on proHB- 
EGF/DTR activity is unknown but probably reflects the tight 
association of the two transmembrane proteins, for example: 
(a) ProHB-EGF/DTR is a relatively small molecule on the 
cell surface, and might be covered with other membrane pro- 
teins. Association of CD9/DRAP27 with proHB-EGF/DTR 
might open appropriate space to give access to EGFR. (b) 
ProHB-EGF/DTR and CD9/DRAP27  may associate with 
other molecules to form a functional juxtacrine device, or 
CD9/DRAP27 may mediate the association of proHB-EGF/ 
DTR and the third molecule resulting in the formation of an 
active juxtacrine complex. 
A novel finding of this study is that CD9/DRAP27, a pro- 
tein previously shown to be involved in platelet aggregation 
(22, 45), association with small GTP-binding proteins (41) 
and sensitivity to DT (8, 25, 32) also has an unexpected func- 
tional role in regulating cell growth. Indeed, this study may 
be the first demonstration that insoluble cell surface-asso- 
ciated growth factors can be potentiated in their growth fac- 
tor activity, in the case of proHB-EGF/DTR, by another 
transmembrane protein, CD9/DRAP27. Previously, soluble 
paracrine growth factors have been shown to be potentiated 
by other molecules. For example, heparin potentiates the mi- 
togenic activity of FGF-1  (40, 48),  FGF-2 (39,  52),  and 
VEGF (15). However, unlike proHB-EGF/DTR, there is no 
evidence as yet that soluble HB-EGF, a potent mitogen for 
SMC, fibroblasts (18), and keratinocytes (16, 30), needs to 
be potentiated by any factors to be optimally bioactive. Thus, 
it may be that the soluble and insoluble forms of HB-EGF 
are regulated differently. If one imagines cell-associated HB- 
EGF, which has a cytoplasmic domain, to be a receptor with 
the ectodomain of EGFR as the ligand, then an analogy can 
be made to other receptors whose binding of ligand is en- 
hanced by the presence of cell surface transmembrane pro- 
teins. For example TGF-~ binding to its high affinity recep- 
tor is dependent on interaction of type I and II receptors with 
the type III receptor, betaglycan (29,  50). 
It is still unclear whether CD9/DRAP27 could associate 
with other membrane-anchored growth factors and upregu- 
late their mitogenic activities. Although upregulation of the 
mitogenic activity of proTGF-ot was not observed in L cells 
coexpressed  with  CD9/DRAP27,  proTGF-ot  may  form  a 
complex with CD9/DRAP27. Since it has been reported that 
proTGF-ct associates with a kinase complex, suggesting the 
existence of  two directional signaling between proTGF-ot and 
EGFR (44), CD9/DRAP27 might be involved in a reverse 
mode of  the signaling. It is under way to investigate the regu- 
lation of other membrane-anchored growth factor activities 
such as proAR, pro/~-cellulin,  and proheregulin. 
These  studies  indic.ate  that juxtacrine  mechanisms  of 
regulating growth and differentiation, first shown for TGF-, 
(1,  4,  6,  51) may be more complex than previously envi- 
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tors reported recently (44),  as seems to be  the case  for 
growth factor receptors (28).  Since transmembrane growth 
factors may play a key role in regulating growth and differen- 
tiation, further investigation is needed to elucidate the co- 
factors that modulate  juxtacrine activity and the mechanisms 
by which they act. 
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